Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

Vandana Gupta, Dave Singh

    Research output: Contribution to journalArticlepeer-review


    Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction. Long-acting bronchodilators improve lung function and relieve dyspnea. Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. Aclidinium bromide is delivered using the Genuair ® device, which is an easy to use multidose dry powder inhaler. Aclidinium bromide is rapidly metabolized in the plasma, so there is low systemic exposure that minimizes the anticholinergic side effects. This new long-acting bronchodilator provides effective bronchodilation with minimal side effects. © 2012 Expert Reviews Ltd.
    Original languageEnglish
    Pages (from-to)581-588
    Number of pages7
    JournalExpert review of respiratory medicine
    Issue number6
    Publication statusPublished - Dec 2012


    • aclidinium bromide
    • anticholinergics
    • bronchodilator
    • chronic obstructive pulmonary disease
    • lung function


    Dive into the research topics of 'Aclidinium bromide for the treatment of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

    Cite this